Skip to Main Content
An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Risk of Prostate Cancer Death in the PLCO Cohort Based on a Four Kallekrein Panel

Principal Investigator

Name
Jonathan Shoag

Degrees
M.D.

Institution
Case Western Reserve University

Position Title
Assistant Professor, Department of Urology, School of Medicine

Email
jxs218@case.edu

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-912

Initial CDAS Request Approval
Feb 16, 2022

Title
Risk of Prostate Cancer Death in the PLCO Cohort Based on a Four Kallekrein Panel

Summary
Baseline PSA has long been used as a screening and risk assessment tool in men with suspected or confirmed prostate cancer. The goal of this project is to evaluate the association between a four kallikrein panel (total PSA, free PSA, intact PSA, and human kallikrein-related peptidase 2) and prostate cancer mortality for patients in the PLCO Cohort and compare the predictive power of the four kallikrein score with that of baseline PSA.

Aims

- Evaluate the predictive power of a four kallikrein panel for prostate cancer specific mortality

Collaborators

N/A